Abstract
Multiparametric MRI (mpMRI) plays a critical role in the detection, staging and risk stratification of prostate cancer (PCa). There are two widely accepted structured reporting systems used for interpretation of mpMRI of the prostate - PI-RADS v2.1 and Likert. Both these systems demonstrate good diagnostic performance with high cancer detection rates however have key conceptual differences. In this commentary, the authors highlight the individual strengths and areas of potential improvement as well as emphasize the need for continued clinical validation for these interpreting and reporting systems.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
